DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
Public ClinicalTrials.gov record NCT04014075. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer. They must have human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) cancer: * that cannot be removed surgically * that has moved to other parts of the body * that got worse during or after treatment that included trastuzumab The study will enroll about 80 participants. Sites will be in North America and the European Union.
Study identification
- NCT ID
- NCT04014075
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 79 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2019 (Actual)
- Primary completion
- Nov 8, 2021 (Actual)
- Completion
- Feb 13, 2024 (Actual)
- Last update posted
- Apr 3, 2025
2019 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | — |
| USC Norris Comprehensive Cancer Center Hospital | Los Angeles | California | 90033 | — |
| Pacific Cancer Care | Monterey | California | 93940 | — |
| UCLA Health | Santa Monica | California | 90404 | — |
| Hartford Hospital | Hartford | Connecticut | 06102 | — |
| MidState Medical Center | Meriden | Connecticut | 06451 | — |
| The Hospital of Central Connecticut | New Britain | Connecticut | 06052 | — |
| Smilow Cancer Hospital at Yale-New Haven | New Haven | Connecticut | 06511 | — |
| Miami Cancer Institute, Baptist Health South Florida | Miami | Florida | 33176 | — |
| University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM | Chicago | Illinois | 60637 | — |
| Kansas University Cancer Center | Kansas City | Kansas | 66205 | — |
| Massachusetts General Hospital (MGH) | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center (BIDMC) | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Alvin J. Siteman Cancer Center Washington University | St Louis | Missouri | 63110 | — |
| Northwell Health Cancer Institute | Lake Success | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Lehigh Valley Health Network | Allentown | Pennsylvania | 18103 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Washington/Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04014075, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2025 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04014075 live on ClinicalTrials.gov.